CTOs on the Move


 
More than an OEM company, IntriCon is invested in creating a hearing healthcare system to offer individuals hearing help at a cost they can afford.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

21st Century Biochemicals

21st Century Biochemicals is a Marlborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Centrix Pharmaceutical

Centrix Pharmaceutical is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vifor Pharma

Vifor Pharma is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ionis Pharmaceuticals

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.

NeuBase Therapeutics

NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes